Hard to Treat Diseases, Inc. (HTDS) Reports on Positive Influence of Hyperbaric Oxygenation on Recovery from Brain Trauma

BELGRADE, Serbia, April 6 /PRNewswire/ - Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com is pleased to announce that researchers from its Slavica BioChem (www.slavicbiochem.com) division have presented their results at the 8th World Congress on the Brain Injury, held in Washington, DC, March 10-14, 2010, under the auspices of The International Brain Injury Association (IBIA) http://www.internationalbrain.org/. The Slavica team presented results which show the potential beneficial effects of hyperbaric oxygenation after traumatic brain injury. The IBIA World Congress is the largest gathering of international professionals working in the field of brain injury. Experts of different background took part in this Congress: scientists, physicians, psychologists and neuropsychologists, therapists, social workers, nurses and other professionals involved in the field of brain injury. The Organizers reported the 2010 meeting was the largest IBIA meeting ever organized, with more than 1000 participants and over 650 accepted abstracts.

Dr. Sanja Pekovic, Chief Project Scientist of HTDS, said: "This Congress was an excellent opportunity to get insight into the state-of-the-art research, covering all from the basic science to the clinical aspects of brain injury, as well as for establishing important contacts with international professionals involved in the brain injury research and the care of people with acquired brain injury. At the same time, we were able to present our results in a summary Poster format which was available for review by attendees. Hyperbaric oxygen (HBO) has been used as a primary or adjunctive therapy over the last 50 years with controversial results, both in experimental and clinical studies. However, mechanisms of HBO action have not been elucidated completely. Our results, obtained in the animal studies, shed more light to this which was very attractive for the numerous scientists and medical doctors. We had 3h long session with the attendees of our poster presentation in order to discuss all the questions on this topic.

Dr. Sanja Pekovic added: "The experiments were performed on rats, but we used the same type of hyperbaric chambers which are used for human subjects. These HBO treatments were conducted in collaboration with the medical doctors from the Hyperbaric Medical Center, School of Medicine, University of Belgrade, Serbia. Our previous experiments showed that repetitive HBO treatments significantly reduced neuronal loss and degeneration, suggesting that HBO was able to attenuate the effects of brain damage by reducing the progression of neuronal injury. These data encouraged us to continue our work. The most recent experiments (presented at the 8th World Congress on Brain Injury) revealed new beneficial effects of HBO treatment on glial scarring and inflammatory processes after traumatic brain injury".

In summary, Dr. Sanja Pekovic concluded: "Results presented here for the first time showed that HBO treatment reduces expression of the promoters of inflammatory responses. Additionally, our experiments point to HBO-induced suppression of astrogliosis and prevention of glial scarring after traumatic brain injury, and recommend HBO treatment as an attractive therapeutic tool for improving recovery from head injury."

In other company news, As the company does not subscribe to Pink Sheets filing service poster of the above release will be posted on the company web site www.htdsmedical.com shortly, and on the company' IR web site Mina Mar Group News and Filings Section www.minamargroup.net. Mr. Michael Arnkvarn CEO of Melem Secrets HTDS Skin Care Product Lines and Dr. Sanja Pekovic of Slavica Bio Chem have confirmed their attendance at the shareholders meeting on April 9 in Toronto Canada, where they will greet shareholders and present future vision for the company.

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorhub.com and other posters, and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.